PE20030262A1 - Composiciones farmaceuticas que comprende compuestos lipofilicos, acido graso y/o sales de acido graso - Google Patents

Composiciones farmaceuticas que comprende compuestos lipofilicos, acido graso y/o sales de acido graso

Info

Publication number
PE20030262A1
PE20030262A1 PE2002000471A PE2002000471A PE20030262A1 PE 20030262 A1 PE20030262 A1 PE 20030262A1 PE 2002000471 A PE2002000471 A PE 2002000471A PE 2002000471 A PE2002000471 A PE 2002000471A PE 20030262 A1 PE20030262 A1 PE 20030262A1
Authority
PE
Peru
Prior art keywords
fatty acid
compounds
lipofilic
pharmaceutical compositions
ammonium
Prior art date
Application number
PE2002000471A
Other languages
English (en)
Inventor
Karsten Maeder
Hans Steffen
Lukas Christoph Scheibler
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20030262A1 publication Critical patent/PE20030262A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Nutrition Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Physiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Position Fixing By Use Of Radio Waves (AREA)

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE a)COMPUESTOS SOLIDOS FARMACEUTICAMENTE ACTIVOS QUE POSEEN UN PUNTO DE FUSION MAYOR O IGUAL A 37°C TAL COMO UN INHIBIDOR DE LIPASA DE PREFERENCIA ORLISTAT (10 mg A 240mg) O COMPUESTOS LIPOFILICOS; b)ACIDO GRASO C8-C24 SATURADO O NO SATURADO TAL COMO ACIDO LAURICO, MIRISTICO, PALMITICO, ESTEARICO, ENTRE OTROS; O UNA SAL DE ACIDO GRASO TAL COMO SAL DE AMONIO, BIS(2-HIDROXIETIL)AMONIO, DIETANOLAMONIO, TRIETANOLAMONIO, SODIO, POTASIO, MAGNESIO, CALCIO; c)EXCIPIENTES FARMACEUTICAMENTE ACEPTABLES TAL COMO ESTER DE SACAROSA, LACTOSA, MANITOL, TALCO, SORBITOL, POLIVINILPIRROLIDONA, ENTRE OTROS; CARACTERIZADA PORQUE ACIDOS GRASOS PROTONADOS DISMINUYEN EL PUNTO DE FUSION DE LOS COMPUESTOS LIPOFILICOS EN CONTACTO CON UNA SOLUCION ACUOSA (FLUIDO GASTRICO O BUCAL) CON UN pH MENOR O IGUAL A 8, POR LO QUE MEJORA LA BIODISPONIBILIDAD DE LA COMPOSICION
PE2002000471A 2001-06-06 2002-06-05 Composiciones farmaceuticas que comprende compuestos lipofilicos, acido graso y/o sales de acido graso PE20030262A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP01113792 2001-06-06

Publications (1)

Publication Number Publication Date
PE20030262A1 true PE20030262A1 (es) 2003-03-19

Family

ID=8177653

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2002000471A PE20030262A1 (es) 2001-06-06 2002-06-05 Composiciones farmaceuticas que comprende compuestos lipofilicos, acido graso y/o sales de acido graso

Country Status (21)

Country Link
US (1) US6730319B2 (es)
EP (1) EP1399153B1 (es)
JP (1) JP4558313B2 (es)
KR (1) KR100613946B1 (es)
CN (1) CN1514726B (es)
AR (1) AR037490A1 (es)
AT (1) ATE375155T1 (es)
AU (1) AU2002319189B2 (es)
BR (1) BR0210267A (es)
CA (1) CA2448035C (es)
DE (1) DE60222898T2 (es)
DK (1) DK1399153T3 (es)
ES (1) ES2292782T3 (es)
GT (1) GT200200105A (es)
MX (1) MXPA03011041A (es)
PA (1) PA8546501A1 (es)
PE (1) PE20030262A1 (es)
PT (1) PT1399153E (es)
UY (2) UY3901U (es)
WO (1) WO2002098413A2 (es)
ZA (1) ZA200309099B (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6616942B1 (en) * 1999-03-29 2003-09-09 Soft Gel Technologies, Inc. Coenzyme Q10 formulation and process methodology for soft gel capsules manufacturing
US7364752B1 (en) 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
DE60028754T2 (de) * 1999-11-12 2007-05-31 Abbott Laboratories, Abbott Park Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US8900497B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for making a film having a substantially uniform distribution of components
US20190328679A1 (en) 2001-10-12 2019-10-31 Aquestive Therapeutics, Inc. Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US20110033542A1 (en) 2009-08-07 2011-02-10 Monosol Rx, Llc Sublingual and buccal film compositions
US8603514B2 (en) 2002-04-11 2013-12-10 Monosol Rx, Llc Uniform films for rapid dissolve dosage form incorporating taste-masking compositions
US20070281003A1 (en) 2001-10-12 2007-12-06 Fuisz Richard C Polymer-Based Films and Drug Delivery Systems Made Therefrom
US8900498B2 (en) 2001-10-12 2014-12-02 Monosol Rx, Llc Process for manufacturing a resulting multi-layer pharmaceutical film
US8663687B2 (en) * 2001-10-12 2014-03-04 Monosol Rx, Llc Film compositions for delivery of actives
US10285910B2 (en) 2001-10-12 2019-05-14 Aquestive Therapeutics, Inc. Sublingual and buccal film compositions
US11207805B2 (en) 2001-10-12 2021-12-28 Aquestive Therapeutics, Inc. Process for manufacturing a resulting pharmaceutical film
US7357891B2 (en) 2001-10-12 2008-04-15 Monosol Rx, Llc Process for making an ingestible film
US8765167B2 (en) 2001-10-12 2014-07-01 Monosol Rx, Llc Uniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
AU2002343555A1 (en) * 2001-11-14 2003-05-26 Texas Tech University Eutectic-based self-nanoemulsified drug delivery system
US8372430B2 (en) * 2002-12-17 2013-02-12 The Procter & Gamble Company Compositions, methods, and kits useful for the alleviation of gastrointestinal effects
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
PT1673359E (pt) * 2003-09-12 2009-10-06 Ranbaxy Lab Ltd Processo para a preparação de formas cristalinas de orlistat
US8124072B2 (en) 2003-09-29 2012-02-28 Soft Gel Technologies, Inc. Solubilized CoQ-10
EP1670325A1 (en) * 2003-09-29 2006-06-21 Soft Gel Technologies, Inc. SOLUBILIZED CoQ-10
JP4954450B2 (ja) * 2004-06-14 2012-06-13 ビーエーエスエフ ビューティ ケア ソリューションズ フランス エスエーエス 弾性繊維形成の不全、欠損又は無秩序による病状に対処するための、リシルオキシダーゼのアイソフォームの活性の誘導
KR100669497B1 (ko) * 2005-08-17 2007-01-16 보람제약주식회사 안정성과 용출률이 뛰어난 약리학적 조성물 및 그 제조방법
US20090203780A1 (en) * 2006-06-27 2009-08-13 Luisa Gambelli Use of a Polyunsaturated Fatty Acid Compound
US8343541B2 (en) 2007-03-15 2013-01-01 Soft Gel Technologies, Inc. Ubiquinol and alpha lipoic acid compositions
US20100196464A1 (en) * 2007-09-17 2010-08-05 Dr. Reddy's Laboratories Limited Orlistat pharmaceutical formulations
WO2009050720A1 (en) * 2007-10-15 2009-04-23 Inventis Dds Pvt Limited Pharmaceutical composition of orlistat
US8298583B2 (en) 2007-10-19 2012-10-30 Monosol Rx, Llc Film delivery system for tetrahydrolipstatin
PL216542B1 (pl) 2008-03-20 2014-04-30 Zakłady Farmaceutyczne POLPHARMA Spółka Akcyjna Sposób wytwarzania stabilnej kompozycji orlistatu w postaci kapsułkowanego proszku
KR200449701Y1 (ko) * 2008-08-21 2010-08-02 한복순 월풀욕조의 잔물 제거장치
WO2010042499A1 (en) * 2008-10-06 2010-04-15 Banner Pharmacaps, Inc. Stable solutions of orlistat for pharmaceutical dosage forms
BRPI0901602B8 (pt) 2009-04-03 2021-05-25 Ems S/A formulação farmacêuticas
US9149959B2 (en) 2010-10-22 2015-10-06 Monosol Rx, Llc Manufacturing of small film strips
KR101593539B1 (ko) * 2015-07-03 2016-02-15 고려대학교 산학협력단 지방조직 중성지질 분해 효능을 가지는 아젤라산 조성물
BR112018072539A2 (pt) 2016-05-05 2019-03-26 Aquestive Therapeutics, Inc. composições de epinefrina de administração aumentada
US11273131B2 (en) 2016-05-05 2022-03-15 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced permeation
US10786475B2 (en) 2018-02-20 2020-09-29 Korea University Research And Business Foundation Method for preventing, treating, or improving fatty liver by administering effective amounts of azelaic acid to a subject
US11931330B2 (en) 2018-02-20 2024-03-19 Korea University Research And Business Foundation Composition for promoting skeletal muscle activity via induction of mitochondrial biogenesis comprising of azelaic acid as an active ingredient
CN108354910A (zh) * 2018-05-17 2018-08-03 安士制药（中山）有限公司 一种西甲硅油软胶囊
US20220015404A1 (en) * 2018-12-06 2022-01-20 International Flavors & Fragrances Inc. Traumatic acid compositions and methods for taste modulation
EP3890512A4 (en) * 2018-12-06 2022-08-24 International Flavors & Fragrances Inc. BOEHMERIA NIVEA COMPOSITIONS AND METHODS FOR TASTE MODULATION
EP4009961A1 (en) * 2019-08-08 2022-06-15 Evonik Operations GmbH Solubility enhancement of poorly soluble actives

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3013839A1 (de) 1979-04-13 1980-10-30 Freunt Ind Co Ltd Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung
DE3217071A1 (de) 1982-05-06 1983-11-10 Rüdiger Dr. 6365 Rosbach Gröning Arzneimittel fuer die perorale applikation mit verbesserter biologischer verfuegbarkeit der wirkstoffe
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
FI912955A (fi) 1990-06-25 1991-12-26 Res Found Mental Hygiene Antimikroba fettsyrasammansaettningar.
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
JP2682353B2 (ja) * 1991-11-20 1997-11-26 武田薬品工業株式会社 経口用医薬組成物およびその製造法
DE4440337A1 (de) 1994-11-11 1996-05-15 Dds Drug Delivery Services Ges Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
JPH1081621A (ja) * 1996-04-01 1998-03-31 Takeda Chem Ind Ltd 経口投与用医薬組成物
DE19739031A1 (de) 1997-09-05 1999-03-11 Suwelack Nachf Dr Otto Mittel zur peroralen Verabreichung, seine Herstellung und Verwendung
GB9727131D0 (en) 1997-12-24 1998-02-25 Knoll Ag Therapeutic agents
KR20010079635A (ko) 1998-08-14 2001-08-22 프리돌린 클라우스너, 롤란드 비. 보레르 리파아제 저해제를 함유하는 약학 조성물
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
AR025587A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones en dispersion que contienen inhibidores de lipasa
AR025609A1 (es) 1999-09-13 2002-12-04 Hoffmann La Roche Formulaciones lipidas solidas
US6348492B1 (en) 1999-10-29 2002-02-19 2Pro Chemical Oxetanone derivatives
AU1238101A (en) 1999-10-29 2001-05-14 John Jason Gentry Mullins Oxetanone derivatives
JP2004525856A (ja) * 1999-11-04 2004-08-26 モンサント テクノロジー エルエルシー コレステロールを低下させるステロール組成物、調製及び使用方法

Also Published As

Publication number Publication date
DE60222898T2 (de) 2008-07-24
EP1399153B1 (en) 2007-10-10
US20030039686A1 (en) 2003-02-27
KR100613946B1 (ko) 2006-08-18
WO2002098413A2 (en) 2002-12-12
ZA200309099B (en) 2005-05-25
PA8546501A1 (es) 2003-01-24
ATE375155T1 (de) 2007-10-15
AR037490A1 (es) 2004-11-17
ES2292782T3 (es) 2008-03-16
GT200200105A (es) 2003-02-26
DE60222898D1 (de) 2007-11-22
BR0210267A (pt) 2004-07-20
CA2448035C (en) 2009-11-03
UY3901U (es) 2002-07-31
EP1399153A2 (en) 2004-03-24
US6730319B2 (en) 2004-05-04
UY27320A1 (es) 2003-02-28
CA2448035A1 (en) 2002-12-12
CN1514726B (zh) 2010-10-06
JP4558313B2 (ja) 2010-10-06
PT1399153E (pt) 2007-12-31
KR20040010681A (ko) 2004-01-31
CN1514726A (zh) 2004-07-21
WO2002098413A3 (en) 2003-02-27
MXPA03011041A (es) 2004-03-19
DK1399153T3 (da) 2008-01-07
JP2004532272A (ja) 2004-10-21
AU2002319189B2 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
PE20030262A1 (es) Composiciones farmaceuticas que comprende compuestos lipofilicos, acido graso y/o sales de acido graso
NO2022019I1 (no) Eribulin eller et farmasøytisk akseptabelt salt derav - forlenget SPC
JP2004532272A5 (es)
AR100790A2 (es) COMPUESTOS HETEROCÍCLICOS, ACTIVOS COMO INHIBIDORES DE b-LACTAMAS
HUP0401816A2 (hu) Prosztaglandin-készítmények és alkalmazásuk erekciós zavarok kezelésére szolgáló gyógyszerek előállítására
DE60222803D1 (de) Orale kapselformulierung mit verbesserter physikalischer stabilität
PE20030399A1 (es) Formas de administracion de propiverina o sus sales farmaceuticamente aceptables con liberacion prolongada de la sustancia activa
CU23198A3 (es) COMPUESTOS FARMACéUTICAMENTE ACTIVOS
MEP33708A (en) Pharmaceutical compositions comprising a hmg coa reductase inhibitor
ES2063146T3 (es) Composiciones farmaceuticas que contienen acido n-(3,4-dimetoxicinamoil)-antranilico.
AR013477A1 (es) Prostaglandinas de tetrahidro sustituido c16-20 aromatico utiles como agonistas de fp.
ES2283535T5 (es) Producto para el cuidado de lentes que contiene dexpantenol.
ES2183595T3 (es) Empleo de ectoina o derivados de ectoina en formulaciones.
MXPA04003540A (es) Utilizacion de un copolimero para producir una forma galenica que contiene un peptido o proteina como agente activo.
GT200200044A (es) Compuestos farmaceuticamente activos
PE20030303A1 (es) FORMULACIONES DE INTERFERON ß HUMANO
PE20030092A1 (es) Formulacion de una solucion de inhalacion con una sal de tiotropio
MX9207204A (es) Preparado farmaceutico y procedimiento para su fabricacion.
ES2052530T3 (es) Composiciones farmaceuticas liofilizadas de acidos carboxilicos de fenilquinolina.
SE8601799L (sv) (-)-1beta-etyl-1alfa-hydroximetyl-1,2,3,4,6,7,12,12balfa-iktahydroindolo/2,3-a/-kinolizin, forfarande for dess framstellning och farmaceutiska beredningar innehallande densamma
IT1209644B (it) Composti farmacologicamente attivi.
PE20001610A1 (es) Composiciones de esteres de acido carbamico utiles para el tratamiento viral
DE69002586D1 (de) Pradimicin-derivate.
ES2176258T3 (es) Uso de penciclovir en el tratamiento de la neuralgia post-herpeticas. a
MXPA04002868A (es) Preparacion de solucion acuosa de ecabet sodico.

Legal Events

Date Code Title Description
FD Application declared void or lapsed